Disaccharidase deficiency in amniotic fluid from cases of cystic fibrosis

Prenatal diagnosis of cystic fibrosis by microvillar enzyme assay on a sequence of 258 pregnancies

Prenatal diagnosis of cystic fibrosis by microvillar enzyme assay on amniotic fluid supernatant has been carried out on 258 sequential pregnancies with a 1 in 4 recurrence risk, all with known outcome. In general the three enzymes evaluated, gamma-glutamyltranspeptidase, aminopeptidase M and the intestinal isoenzyme of alkaline phosphatase, showed a high degree of concordance. However, there were two unusual patterns of microvillar enzyme activity; in seven cases a low gamma-glutamyltranspeptidase activity was associated with elevated values of intestinal alkaline phosphatase, and in ten cases there were isolated low values of intestinal alkaline phosphatase. The former pattern was found to be associated with cystic fibrosis in five cases, while the latter was associated with a normal outcome in all ten cases. A retrospective analysis of enzyme values suggested that the optimal system for minimizing false positives and false negatives was to define foetal cystic fibrosis as a sample where two of the three microvillar enzymes were below a cut-off of half the median value for the gestational week. If such scoring were applied to the cases where conventional microvillar enzyme patterns were observed, the false positive rate was 2.3% and the false negative rate 4.4% between 17 and 20 weeks of gestation.

Fetal diagnosis of inborn errors of metabolism

Nearly 4000 different human disorders are supposed or known to be due to a single gene mutation. In about 10%, an early diagnosis is possible by the demonstration of specific abnormalities of metabolites in blood and/or urine, an abnormal structure/function of a particular (enzyme) protein or by the (in)direct demonstration of the gene mutation using DNA analysis. These methods of molecular analysis can often also be used for carrier detection. Early identification of couples at risk of handicapped offspring followed by genetic counselling forms the basis for prevention. Follow-up studies have shown that more than half of the couples at risk of a child with a genetic disease refrain from pregnancy. An important alternative for couples at risk is prenatal monitoring and selective abortion. During the last 10-15 years, the technology of fetal diagnosis of genetic diseases has improved and the number of Mendelian disorders that can be diagnosed in utero has increased to more than 100. In the second-trimester of pregnancy, about two dozen inborn errors of metabolism have been diagnosed by metabolite analysis of amniotic fluid supernatant using gas chromatography-mass spectrometry or electrophoretic methods. About 5000 pregnancies at risk of different types of haemoglobinopathy, haemophilia, alpha-1-antitrypsin deficiency and a few other diseases not expressed in amniotic fluid cells have been investigated by biochemical analysis after fetal blood sampling. The most common approach towards fetal diagnosis of inborn errors of metabolism has been the demonstration of a specific enzyme deficiency in cultured amniotic fluid cells. In this way some 60 different diseases have been diagnosed, usually after 2-4 weeks of cultivation after amniocentesis at 16 weeks gestation. In addition, some 20 other Mendelian disorders have been diagnosed in utero by ultrasonography and non-biochemical analysis of amniotic fluid cells or fetal skin biopsies. The introduction of chorionic villus sampling has offered the possibility of first-trimester fetal diagnosis of a large number of Mendelian disorders. The overall diagnostic experience until mid-1986 amounts to about 1500 pregnancies at risk. Some 45 different inborn errors have been diagnosed by enzyme assays directly on chorionic villus homogenate or after incubation with radiolabelled precursors of intact villi followed by chromatography or other types of analysis. In a few instances, cell cultivation for a period of 2-3 weeks is required to establish a reliable biochemical diagnosis.

Fetal diagnosis of cystic fibrosis

Two different methods of prenatal diagnosis of CF are currently available. Both are usually only suitable for couples with a 1 in 4 risk of bearing an affected child. The method of choice is first trimester diagnosis on a chorionic villus sample using linked DNA probes. The advantages are: 1. The very high degree of accuracy of diagnosis, 2. The opportunity of first trimester termination of pregnancy when the fetus is affected. The disadvantages are: 1. The need for a blood sample from an index affected child to establish phase, 2. The requirement for early workup of the nuclear family to ascertain informativeness, 3. The chance that some families will be uninformative or only partially informative for available DNA probes. An alternative form of diagnosis is that using microvillar enzyme testing on second trimester amniocentesis samples. The advantages are: 1. It is suitable for all pregnancies with a 1 in 4 risk of CF, 2. No prior workup of the family is required, 3. Assays can be completed within one hour of receipt of the sample. The disadvantages are: 1. The accuracy of diagnosis leaves some scope for error, 2. If termination of pregnancy is indicated this can only be carried out at about 18 or 19 weeks of gestation.

Prenatal detection of intestinal obstructions, aneuploidy syndromes, and cystic fibrosis by microvillar enzyme assays (disaccharidases, alkaline phosphatase, and glutamyltransferase) in amniotic fluid

Microvillar enzymes (disaccharidases, alkaline phosphatase, and gamma-glutamyltransferase) were assayed in amniotic fluid from pregnancies with normal and abnormal fetuses to determine their specificity and reliability for the prenatal detection of intestinal obstructions and cystic fibrosis. All fetuses with imperforate anus, duodenal atresia, jejuno-ileal atresia, multiple intestinal atresia, or other forms of intestinal obstructions, with or without associated ventral wall defect or aneuploidy syndrome, showed diminished microvillar enzyme activities below the normal range of control amniotic fluid samples. The exclusively intestinal hydrolases maltase, sucrase, palatinase, and alkaline phosphatase were the most reliable and sensitive markers to detect intestinal obstructions whereas more widely distributed trehalase and gamma-glutamyltransferase activities were less sensitive. The combination of intestinal disaccharidase maltase, sucrase or palatinase and ALP assays is more accurate for prenatal diagnosis of CF than a combination of intestinal ALP and GGTF assays.